Safety, Tolerance, and Efficacy of Extended-Release Niacin Monotherapy for Treating Dyslipidemia Risks in Persons With Chronic Tetraplegia: A Randomized Multicenter Controlled Trial Mark S. Nash, PhD, John E. Lewis, PhD, Trevor A. Dyson-Hudson, MD, Yaga Szlachcic, MD, Florence Yee, PharmD, Armando J. Mendez, PhD, Ann M. Spungen, EdD, William A. Bauman, MD Archives of Physical Medicine and Rehabilitation Volume 92, Issue 3, Pages 399-410 (March 2011) DOI: 10.1016/j.apmr.2010.06.029 Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 2 Effects of extended-release niacin (ER-N) and placebo on (A) UA, (B) alanine transaminase, (C) aspartate transaminase, (D) alkaline phosphatase, and (E) total bilirubin levels. Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 3 Effects of extended-release niacin (ER-N) and placebo on (A) fasting glycemia and (B) HbA1c level. Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 4 Frequencies of (A) flushing and (B) insomnia and intensities of (C) flushing and (D) insomnia during extended-release niacin (ER-N) monotherapy. Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 5 Effects of extended-release niacin (ER-N) and placebo on levels of (A) HDL-C, (B) LDL-C, (C) TC, (D) TG, and (E) TC/HDL-C and (F) LDL-C/HDL-C ratios (global risk ratios). Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions
Fig 6 Extended-release niacin dose-dependent changes in HDL-C, LDL-C, and TC levels. *P<.05 between baseline and each drug treatment; each bar represents the mean ± SEM value. Archives of Physical Medicine and Rehabilitation 2011 92, 399-410DOI: (10.1016/j.apmr.2010.06.029) Copyright © 2011 American Congress of Rehabilitation Medicine Terms and Conditions